Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12...2930313233343536373839...4748»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date:  Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 27, 2021   
    P=N/A,  N=290, Recruiting, 
    Not yet recruiting --> Recruiting | N=514 --> 290 | Trial completion date: Dec 2024 --> Mar 2026 | Initiation date: Aug 2020 --> Mar 2021 | Trial primary completion date: Aug 2024 --> Mar 2024
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Clinical, Journal:  Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer. (Pubmed Central) -  Apr 24, 2021   
    Not yet recruiting --> Recruiting | N=514 --> 290 | Trial completion date: Dec 2024 --> Mar 2026 | Initiation date: Aug 2020 --> Mar 2021 | Trial primary completion date: Aug 2024 --> Mar 2024 Anlotinib was less effective than platinum-pemetrexed chemotherapy in T790M-negative NSCLC patients after disease progression with first-line EGFR-TKIs therapy failure.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Clinical, P1 data, Clinical Trial,Phase I, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker:  Phase Ib Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer. (Pubmed Central) -  Apr 22, 2021   
    P1, P2
    To the best of our knowledge, this is the first study that has assessed an anti-PD-1 antibody combined with a multi-target antiangiogenic TKI in the front-line setting for NSCLC patients. In view of its encouraging efficacy, durability, and safety profile, sintilimab plus anlotinib represents a novel chemotherapy-free regimen in this patient population.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib. (Pubmed Central) -  Apr 21, 2021   
    These findings suggest that the activation of lysosomal function protects against anlotinib-mediated cell apoptosis via regulating the cellular redox status. Taken together, our results provide novel insights into the regulatory mechanisms of anlotinib on lysosomes, and this information could facilitate the development of potential novel cancer therapeutic agents that inhibit lysosomal function.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment closed, Trial primary completion date, Metastases:  AHNATHY: Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer (clinicaltrials.gov) -  Apr 1, 2021   
    P2,  N=13, Active, not recruiting, 
    This combination could be further evaluated with or without chemotherapy, since no additional toxicity was observed in the combination treatment. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2021 --> Feb 2021
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Clinical, Journal:  Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib. (Pubmed Central) -  Mar 26, 2021   
    Nomograms were developed from clinical features and nutritional indicators to predict the probability of achieving 3-month and 4-month PFS and 7-month and 8-month OS with antiangiogenic therapy for advanced lung cancer. Dynamic changes in body composition before the initiation of treatment contributed to early detection of poor outcome.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Anlotinib Treatment in Steroid Depenent/Refractory cGVHD (clinicaltrials.gov) -  Mar 24, 2021   
    P2,  N=5, Terminated, 
    Dynamic changes in body composition before the initiation of treatment contributed to early detection of poor outcome. N=40 --> 5 | Trial completion date: Feb 2022 --> Mar 2021 | Not yet recruiting --> Terminated | Trial primary completion date: Feb 2021 --> Sep 2020; the efficency is not good enough to enroll more patients
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Anlotinib suppresses metastasis and multidrug resistance via dual blockade of MET/ABCB1 in colorectal carcinoma cells. (Pubmed Central) -  Mar 24, 2021   
    The CRC liver metastasis and subcutaneously implanted xenograft model testified that anlotinib could inhibit proliferation and liver metastasis in CRC cells. Such an observation suggested that a combination of anlotinib with anti-cancer drugs could attenuate angiogenesis, metastasis, proliferative, and multidrug resistance, which constitutes a novel treatment strategy for CRC patients with metastasis.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment closed, Enrollment change, Trial completion date:  Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer (clinicaltrials.gov) -  Mar 23, 2021   
    P1,  N=8, Active, not recruiting, 
    Such an observation suggested that a combination of anlotinib with anti-cancer drugs could attenuate angiogenesis, metastasis, proliferative, and multidrug resistance, which constitutes a novel treatment strategy for CRC patients with metastasis. Recruiting --> Active, not recruiting | N=18 --> 8 | Trial completion date: Dec 2020 --> Jun 2021
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal, PD(L)-1 Biomarker, IO biomarker:  anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. (Pubmed Central) -  Mar 23, 2021   
    In conclusion, our results demonstrate that PD-L1 high expression on VECs inhibits the infiltration of CD8 T cells, whereas promotes the aggregation of FoxP3 T cells into tumor tissues, thus becoming an "immunosuppressive barrier". Anlotinib can ameliorate the immuno-microenvironment by downregulating PD-L1 expression on VECs to inhibit tumor growth.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature. (Pubmed Central) -  Mar 23, 2021   
    Multi-omics analyses revealed that anlotinib had a profound inhibitory effect on ribosome, and regulated cell cycle, RNA metabolism and lysosome. Based on the multi-omics results and available data deposited in public databases, an anlotinib-related gene signature was further constructed to identify a subgroup of pancreatic cancer patients who had a dismal prognosis and might be responsive to anlotinib.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date, Trial primary completion date, Metastases:  Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Mar 18, 2021   
    P2,  N=48, Recruiting, 
    Based on the multi-omics results and available data deposited in public databases, an anlotinib-related gene signature was further constructed to identify a subgroup of pancreatic cancer patients who had a dismal prognosis and might be responsive to anlotinib. Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Dec 2021
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment open, Metastases:  Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer (clinicaltrials.gov) -  Mar 16, 2021   
    P=N/A,  N=53, Recruiting, 
    The aim of the study is to provide new treatment options for NSCLC patients with brain metastases. Not yet recruiting --> Recruiting
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
    [VIRTUAL] An effective treatment for recurrent and inoperable anaplastic thyroid carcinoma using sintilimab and anlotinib: A case report () -  Mar 13, 2021 - Abstract #AACR2021AACR_4650;    
    Enrolling by invitation --> Completed | Trial completion date: Aug 2021 --> Jan 2021 | Trial primary completion date: Apr 2021 --> Jan 2021 This case showed relatively good prognosis after using anti-angiogenic agent, anlotinib, and immunotherapeutic drug, sintilimab, suggesting a new direction in treating recurrent and inoperable ATC patients, and also providing a new way for cancer patients with PD-L1 negative/TMB-low.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    [VIRTUAL] CoupledCARTMtechnology for treating thyroid cancer () -  Mar 11, 2021 - Abstract #AACR2021AACR_654;    
    In Jun 2016, she enrolled in the Anlotinib experimental group...Recruitment is ongoing to evaluate the safety and efficacy of our CoupledCAR T cells. Further, since our CoupledCAR® technology is a platform technology, we are developing it to treat other solid tumors using different target tumor markers.